

**Antimicrobial Resistance Panel 3:  
*Pseudomonas aeruginosa*, Strain Z-61  
Restoration of Key Mutations (*oprM*, *ampC*,  
*lptE*) to Wild Type**

**Catalog No. NR-55642**

**For research use only. Not for human use.**

**Contributor:**

Thomas Krucker, Ph.D., and Jennifer Leeds, Ph.D., Novartis Institutes for BioMedical Research, Emeryville, California, USA

**Manufacturer:**

BEI Resources

**Product Description:**

*Pseudomonas aeruginosa* (*P. aeruginosa*) strain Z61 (ATCC® 35151™) also known as strain K 799/61, is a drug-hypersusceptible strain generated by chemical mutagenesis of the parent wild-type strain *P. aeruginosa* ATCC® 12055™.<sup>1</sup> *P. aeruginosa* Z61 has been extensively used in studies of antibiotic susceptibility and drug discovery. Although the genetic basis of its hyper susceptibility is not fully understood, mutations in *oprM* (outer membrane efflux pump), *ampC* (inducible β-lactamase) and *lptE* (lipopolysaccharide transporter) genes have been characterized and predicted to be involved.<sup>2</sup> Antimicrobial Resistance Panel 3 consists of 14 strains with varying combinations of wild-type and mutant genes in the strain Z61 or ATCC® 12055™ backgrounds. Seven strains are derived from ATCC® 12055™, in which the wild-type sequences for *oprM*, *ampC* and *lptE* are exchanged for the Z61 mutation, individually or in combination. The remaining seven strains are derived from Z61 by genomic restoration of the wild-type sequences of these gene targets, individually or in combination. The strains comprising this panel are listed in Table 1.

NR-51954 was created by introducing *P. aeruginosa*, strain Z61-specific defect in *lptE*, to the chromosome of ATCC® 12055™.

NR-51955 was created by the chromosomal deletion of *oprM*, and the introduction of *P. aeruginosa*, strain Z61-specific defect in *lptE* to the chromosome of ATCC® 12055™.

NR-51956 was created by chromosomal deletion of *ampC*, and the introduction of *P. aeruginosa*, strain Z61-specific defect in *lptE* to the chromosome of ATCC® 12055™.

NR-51957 was created by the chromosomal deletion of *oprM* and *ampC*, and the introduction of *P. aeruginosa*, strain Z61-specific defect in *lptE* to the chromosome of ATCC® 12055™.

NR-51958 was created by the chromosomal deletion of *ampC* in the parent wild-type strain ATCC® 12055™.

NR-51959 was created by the chromosomal deletion of *oprM* in the parent wild-type strain ATCC® 12055™.

NR-51960 was created by the chromosomal deletion of *oprM* and *ampC* in the wild-type strain ATCC® 12055™.

NR-51961 was created by correcting the *oprM* mutation in the hypersusceptible *P. aeruginosa*, strain Z61 to the wild-type sequence. Wild-type *oprM* sequence derived from *P. aeruginosa*, strain PAO1 was used to carry out the genome correction.

NR-51962 was created by correcting the *ampC* mutation in the hypersusceptible *P. aeruginosa*, strain Z61 to the wild-type sequence. Wild-type *ampC* sequence derived from *P. aeruginosa*, strain PAO1 was used to carry out the genome correction.

NR-51963 was created by correcting the *lptE* mutation in the hypersusceptible *P. aeruginosa*, strain Z61 to the wild-type sequence. Wild-type *lptE* sequence derived from *P. aeruginosa*, strain PAO1 was used to carry out the genome correction.

NR-51964 was created by correcting *lptE* and *ampC* mutations in the hypersusceptible *P. aeruginosa*, strain Z61 to wild-type sequences. Wild-type *lptE* and *ampC* sequences derived from *P. aeruginosa*, strain PAO1 were used to carry out the genome corrections.

NR-51965 was created by correcting *lptE* and *oprM* mutations in the hypersusceptible *P. aeruginosa*, strain Z61 to wild-type sequences. Wild-type *lptE* and *oprM* sequences derived from *P. aeruginosa*, strain PAO1 were used to carry out the genome corrections.

NR-51966 was created by correcting *lptE*, *oprM* and *ampC* mutations in the hypersusceptible *P. aeruginosa*, strain Z61 to wild-type sequences. Wild-type *lptE*, *oprM* and *ampC* sequences derived from *P. aeruginosa*, strain PAO1 were used to carry out the genome corrections.

NR-51967 was created by correcting *ampC* and *oprM* mutations in the hypersusceptible *P. aeruginosa*, strain Z61 to wild-type sequences. Wild-type *lptE* and *oprM* sequences derived from *P. aeruginosa*, strain PAO1 were used to carry out the genome corrections.

Detailed information for each mutant strain, including antibiotic susceptibility profile, is available on the Certificate of Analysis.

**Material Provided:**

Each panel contains one vial of each of the bacterial strains in the panel. Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.

**Note:** If homogeneity is required for your intended use, please purify prior to initiating work.

**Packaging/Storage:**

Each isolate was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze thaw cycles should be avoided.

**Growth Conditions:**

Media:

Tryptic Soy broth or equivalent

Tryptic Soy agar or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 1 day.

**Citation:**

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Antimicrobial Resistance Panel 3: *Pseudomonas aeruginosa*, Strain Z-61 Restoration of Key Mutations (*oprM*, *ampC*, *lptE*) to Wild Type, NR-55642.”

**Biosafety Level: 2**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While

reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

**References:**

1. Zimmermann, W. “Penetration of Beta-Lactam Antibiotics into their Target Enzymes in *Pseudomonas aeruginosa*: Comparison of a Highly Sensitive Mutant with its Parent Strain.” Antimicrob. Agents Chemother. 18 (1980): 94-100. PubMed: 6774666.
2. Shen, X., et al. “Defects in Efflux (*oprM*),  $\beta$ -Lactamase (*ampC*), and Lipopolysaccharide Transport (*lptE*) Genes Mediate Antibiotic Hypersusceptibility of *Pseudomonas aeruginosa* Strain Z61.” Antimicrob. Agents Chemother. 63 (2019): e00784-19. PubMed: 31036686.

ATCC® is a trademark of the American Type Culture Collection.



Table 1: Panel Strains

Item Number	Stain	Background strain	Gene variant(s)
NR-51954	NB52041-CDY0170	<i>P. aeruginosa</i> ATCC® 12055™	<i>lptE<sup>D</sup></i>
NR-51955	NB52041-CDY0171	<i>P. aeruginosa</i> ATCC® 12055™	<i>lptE<sup>D</sup>ΔoprM</i>
NR-51956	NB52041-CDY0172	<i>P. aeruginosa</i> ATCC® 12055™	<i>lptE<sup>D</sup> ΔampC</i>
NR-51957	NB52041-CDY0173	<i>P. aeruginosa</i> ATCC® 12055™	<i>lptE<sup>D</sup> ΔoprM ΔampC</i>
NR-51958	NB52041-CDY0174	<i>P. aeruginosa</i> ATCC® 12055™	<i>ΔampC</i>
NR-51959	NB52041-CDY0175	<i>P. aeruginosa</i> ATCC® 12055™	<i>ΔoprM</i>
NR-51960	NB52041-CDY0176	<i>P. aeruginosa</i> ATCC® 12055™	<i>ΔoprM ΔampC</i>
NR-51961	NB52040-CDY0025	<i>P. aeruginosa</i> strain Z61	<i>oprM</i>
NR-51962	NB52040-CDY0082	<i>P. aeruginosa</i> strain Z61	<i>ampC</i>
NR-51963	NB52040-CDY0083	<i>P. aeruginosa</i> strain Z61	<i>lptE</i>
NR-51964	NB52040-CDY0084	<i>P. aeruginosa</i> strain Z61	<i>ampC, lptE</i>
NR-51965	NB52040-CDY0085	<i>P. aeruginosa</i> strain Z61	<i>oprM, lptE</i>
NR-51966	NB52040-CDY0086	<i>P. aeruginosa</i> strain Z61	<i>oprM, lptE, ampC</i>
NR-51967	NB52040-CDY0087	<i>P. aeruginosa</i> strain Z61	<i>ampC, oprM</i>